Physician profile
Mara Scaramella
NPI 1316240377
$9,721.45
in general payments reported to CMS, 2019-2025
53 companies · $2,242 in 2025
The $2,242 reported for 2025 was more than what 99% of School (Registered Nurse) providers received nationally (typical 2025 total: $120).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,408 · 2022: $1,775 · 2023: $407 · 2024: $1,889 · 2025: $2,242.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,538.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,538.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,826.45 | 2021-2025 | |
| Biohaven Pharmaceuticals, INC. | $893.24 | 2021 | |
| Pfizer INC. | $710.25 | 2024-2025 | |
| Astrazeneca Pharmaceuticals Lp | $644.24 | 2021-2023 | Farxiga |
| Novo Nordisk INC | $501.38 | 2021-2023 | Rybelsus, Ozempic |
| Amgen INC. | $471.73 | 2021-2022 | |
| Lilly USA, LLC | $421.35 | 2021-2024 | Emgality, Reyvow, Amyvid |
| Lundbeck LLC | $409.02 | 2024-2025 | Vyepti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $284.43 | 2022 | |
| Antares Pharma, INC. | $261.59 | 2021-2022 | |
| Tonix Medicines, INC. | $207.87 | 2024-2025 | Zembrace Symtouch |
| Takeda Pharmaceuticals U.S.A., INC. | $203.03 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $196.74 | 2024-2025 | Austedo Xr, Ajovy, Austedo Xr |
| Axsome Therapeutics, INC. | $177.85 | 2025 | Symbravo |
| Janssen Pharmaceuticals, INC | $169.67 | 2023 | Spravato |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mara Scaramella listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.